Nephros Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Nephros kazanç ve gelirinin sırasıyla yıllık 128.2% ve 10.1% oranında artması tahmin edilirken, EPS'nin yıllık 122.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

128.2%

Kazanç büyüme oranı

122.8%

EPS büyüme oranı

Machinery kazanç büyümesi	8.4%
Gelir büyüme oranı	10.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	11 Nov 2024

Gelecekteki son büyüme güncellemeleri

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

May 13

Recent updates

It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)

Oct 03

We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn

Jul 14

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

May 13

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

Dec 18

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Dec 14

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Sep 28

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Aug 13

Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)

Mar 25

At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Mar 04

Announcing: Nephros (NASDAQ:NEPH) Stock Increased An Energizing 131% In The Last Five Years

Jan 28

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:NEPH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	17	1	N/A	N/A	1
12/31/2025	15	0	N/A	N/A	1
12/31/2024	14	0	N/A	N/A	2
9/30/2024	14	-1	N/A	N/A	N/A
6/30/2024	14	-1	-1	-1	N/A
3/31/2024	14	-1	0	0	N/A
12/31/2023	14	-2	1	1	N/A
9/30/2023	14	-2	1	1	N/A
6/30/2023	12	-3	0	0	N/A
3/31/2023	12	-3	-1	-1	N/A
12/31/2022	10	-5	-3	-3	N/A
9/30/2022	10	-5	-4	-3	N/A
6/30/2022	10	-4	-4	-4	N/A
3/31/2022	10	-4	-3	-3	N/A
12/31/2021	10	-3	-2	-1	N/A
9/30/2021	10	-3	-3	-3	N/A
6/30/2021	9	-4	-4	-4	N/A
3/31/2021	9	-4	-5	-5	N/A
12/31/2020	9	-5	-7	-7	N/A
9/30/2020	9	-4	-5	-5	N/A
6/30/2020	10	-4	-4	-4	N/A
3/31/2020	11	-3	-3	-3	N/A
12/31/2019	10	-3	-2	-2	N/A
9/30/2019	9	-4	-3	-3	N/A
6/30/2019	7	-4	-4	-4	N/A
3/31/2019	6	-3	-4	-4	N/A
12/31/2018	6	-3	-4	-4	N/A
9/30/2018	5	-1	-1	-1	N/A
6/30/2018	5	-1	N/A	-1	N/A
3/31/2018	4	-2	N/A	0	N/A
12/31/2017	4	-1	N/A	0	N/A
9/30/2017	3	-3	N/A	-2	N/A
6/30/2017	3	-3	N/A	-2	N/A
3/31/2017	2	-3	N/A	-2	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	2	-3	N/A	-3	N/A
6/30/2016	2	-3	N/A	-3	N/A
3/31/2016	2	-4	N/A	-3	N/A
12/31/2015	2	-3	N/A	-4	N/A
9/30/2015	2	-3	N/A	-3	N/A
6/30/2015	2	0	N/A	-3	N/A
3/31/2015	2	-4	N/A	-3	N/A
12/31/2014	2	-7	N/A	-2	N/A
9/30/2014	2	-2	N/A	-3	N/A
6/30/2014	2	-6	N/A	-2	N/A
3/31/2014	2	-1	N/A	-3	N/A
12/31/2013	2	1	N/A	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NEPH önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: NEPH önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: NEPH önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: NEPH şirketinin gelirinin (yıllık 10.1% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: NEPH şirketinin gelirinin (yıllık 10.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NEPH 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Nephros Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus estimates of losses per share improve by 11%

Consensus EPS estimates upgraded to US$0.035 loss, revenue downgraded

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

Forecast to breakeven in 2025

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nephros, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Nephros, Inc. Launches New HydraGuard 20" UltraFilter

It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)

Consensus estimates of losses per share improve by 11%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Nephros, Inc. to Report Q2, 2024 Results on Aug 08, 2024

We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn

President recently bought US$112k worth of stock

Consensus EPS estimates upgraded to US$0.035 loss, revenue downgraded

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2025

Nephros, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Now 21% undervalued

Now 25% undervalued

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Forecast to breakeven in 2025

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Nephros, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

No longer forecast to breakeven

First quarter 2023 earnings: EPS misses analyst expectations

Nephros, Inc. Announces CEO Changes

Forecast to breakeven in 2024

Consensus EPS estimates fall by 37%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 27% to US$3.00

Less than half of directors are independent

Nephros, Inc. Announces Board Changes

Nephros, Inc. to Report Q4, 2022 Results on Mar 08, 2023

Nephros, Inc. announced delayed 10-Q filing

Price target decreased to US$3.63

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Nephros, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Nephros Appoints Joe Harris to Its Board of Directors

Wes Lobo, Chief Commercial Officer of Nephros, Inc. Resigns, to Be Effective No Later Than September 30, 2022

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Second quarter 2022 earnings: EPS exceeds analyst expectations

Nephros, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

Consensus revenue estimates fall by 17%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$9.33

Nephros, Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings: EPS misses analyst expectations

Nephros, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2022

Price target decreased to US$12.33

Nephros, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021 and for the Year 2022

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.19 loss in 2Q 2020)

Forecast to breakeven in 2023

No longer forecast to breakeven

Consensus revenue estimates fall to US$10.9m

First quarter 2021 earnings released: US$0.06 loss per share (vs US$0.14 loss in 1Q 2020)

Nephros, Inc. Provides Revenue Guidance for the Quarter Ended March 31, 2021